Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting

1

Introduction

00:00 • 3min

2

AML Versus MDS - What's Your Vision?

02:45 • 2min

3

The Face of AML in Older Adults With AML

04:19 • 2min

4

AML and MDS - A Review of the ViALIA Trial

06:25 • 1min

5

The ViALIA Trial - IDH1 Inhibitors and Aesus Ven

07:38 • 5min

6

Aesus Ven Cytopenias Dosing

13:03 • 2min

7

HMMA Venetoclax and A's Event

14:34 • 3min

8

IDH2 and IDH1 - What's Your Take on That?

17:29 • 2min

9

The New IDH Inhibitor Is Approved

19:03 • 5min

10

Do You Think It Will Take a Phase Three Trial?

24:31 • 3min

11

Is There a Guilt to Written Up Trial for TKD?

27:46 • 5min

12

CPX351 vs 3-0-7 in Patients With MDS Type Mutations

32:39 • 2min

13

CPX351 in Secondary AML?

34:46 • 3min

14

The CR Rate Is 50% in P53 Mutant Patients Compared to HMA Venn

37:55 • 4min

15

McGrollumab With P-53 Mutation

41:38 • 5min

16

A's of Venn in KMT2A Rearranged Leukemia

47:07 • 2min

17

Antosplatinib and Landerplenib - What's the Cure Rate?

48:49 • 2min

18

Is There a Sick Inhibitor in CLL?

50:31 • 6min

19

Lusperisps

56:20 • 2min

20

Is It Related to Cytokine Side Effects?

58:05 • 2min

21

Low Dose Leadelitamide in Myeloma

01:00:34 • 5min

22

Oral ASH

01:05:35 • 3min

23

Is There a Risk of Secondary AML in Autologous Transplant?

01:08:16 • 2min